瑞舒伐他汀钙联合阿昔莫司治疗老年高脂血症的效果观察

Therapeutic effect of rosuvastatin calcium combined with acipimox in the treatment of senile hyperlipidemia

目的观察并分析老年高血脂症患者经瑞舒伐他汀钙与阿昔莫司联合治疗的临床效果。方法选择我院就诊的老年高血脂症患者94例,按照治疗先后顺序将患者分为对照组与治疗组,每组47例。对照组治疗用20 mg瑞舒伐他汀钙;治疗组在对照组的基础上同时加用0.25 mg阿昔莫司。观察比较两组临床疗效、不良反应发生情况及治疗前、后血脂水平。结果治疗后,两组的血浆TC、TG、LDL-C水平降低,HDL-C水平升高,且治疗组各指标水平优于对照组(P<0.05)。治疗组治疗总有效率为95.74%,明显高于对照组的87.23%(P<0.05)。治疗过程中,治疗组患者不良反应总发生率为6.38%,与对照组的8.51%比较无显著差异(P>0.05)。结论老年高血脂症患者经瑞舒伐他汀钙与阿昔莫司联合治疗有效率高,能显著降低患者的血浆血脂含量,且有较好的安全性。

Objective To observe and analyze the effect of rosuvstatin calcium combined with acipimox in the treatment of senile hyperlipemia. Methods Ninety four cases of senile hyperlipemia patients treated in our hospital were selected and divided into control group and treatment group according to the treatment sequence, with 47 cases in each group. The con- trol group used rosuvstatin calcium 20 mg, while the treatment group taken acipimox 0.25 mg on the basis of the control group. The treatment effects, adverse reaction rate and the blood lipid levels before and after treatment in the two groups were observed and compared. Results After treatment, the plasma levels of TC, TG and LDL-C decreased and HDL-C levels increased in the two groups, those indexes in the treatment group were better than the control group （P〈0.05）. The total effective rate was 95.74% in the treatment group, which was significantly higher than 87.23% in the control group （P〈 0.05）. During the course of treatment, the overall incidence of adverse reactions was 6.38% in the treatment group and 8.51% in the control group, the difference was not significant （P〉0.05）. Conclusion Rosuvstatin calcium combined with acipimox in the treatment of senile hyperlipemia has high efficiency, which can significantly reduce the patients＂ plasma lipid levels, and have better safety.